Search results
Results from the WOW.Com Content Network
Image showing Gastrointestinal Stromal Tumor after surgical removal. For localized, resectable adult GISTs, if anatomically and physiologically feasible, surgery is the primary treatment of choice. [22]: 69 Surgery can be potentially curative, but watchful waiting may be considered in small tumors in carefully selected situations. [28]
The prognosis for these types of tumors depends heavily on the size of the tumor and the rate of mitosis, however approximately 60 percent of GISTs are diagnosed as benign. [4] Surgery to remove the tumor is the primary treatment method, although imatinib, everolimus, and rapamycin may soon be approved as alternative treatment and management ...
If cancer has spread beyond the uterus, radiation, chemotherapy, and hormonal therapy may be used. If detected in its early stages, survival rates for uterine sarcoma are 66% after 5 years. If cancer has spread beyond the uterus, the survival rate declines to approximately 13-34%.
Gastrointestinal cancer refers to malignant conditions of the gastrointestinal tract (GI tract) and accessory organs of digestion, including the esophagus, stomach, biliary system, pancreas, small intestine, large intestine, rectum and anus. The symptoms relate to the organ affected and can include obstruction (leading to difficulty swallowing ...
The five-year survival rate of borderline tumors and malignant tumors confined to the ovaries are 100% and 70% respectively. If the peritoneum is involved, these rates become 90% and 25%. While the 5-year survival rates of borderline tumors are excellent, this should not be seen as evidence of cure, as recurrences can occur many years later.
Ovarian cancer most often occurs after menopause with 50% of these cancers developing after age 63, the American Cancer Society notes. Symptoms of borderline ovarian tumors are the same as “any ...
Patients in response categories 4-9 should be considered as failing to respond to treatment (disease progression). Thus, an incorrect treatment schedule or drug administration does not result in exclusion from the analysis of the response rate. Precise definitions for categories 4-9 will be protocol specific.
SEER collects and publishes cancer incidence and survival data from population-based cancer registries covering approximately 34.6% of the population of the United States. SEER coverage includes 30.0% of African Americans , 44% of Hispanics, 49.3% of American Indians and Alaska Natives , 57.5% of Asians, and 68.5% of Hawaiian/Pacific Islanders ...